Here are the 10-K annual reports from CRISPR Therapeutics AG (CRSP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CRSP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRSP filings page.
CRISPR Therapeutics describes its business as a leader in CRISPR/Cas9 gene-editing medicines, highlighted by CASGEVY, the first approved CRISPR-based therapy for severe sickle cell disease and transfusion‑dependent beta thalassemia in patients 12 and older across multiple regions.
The company outlines four core franchises: hemoglobinopathies, in vivo liver gene editing, allogeneic CAR T cell therapies for autoimmune diseases and oncology, and regenerative medicine for Type 1 diabetes. It estimates about 60,000 eligible SCD and TDT patients in key Western and Middle Eastern markets.
Pipeline updates include CTX310 in Phase 1b for cardiovascular disease, where a single-course treatment cut ANGPTL3 by up to 89%, triglycerides by up to 84%, and LDL by up to 87% in early data, and CTX611, a long‑acting siRNA Factor XI inhibitor now in Phase 2. Zugo‑cel, its next‑generation allogeneic CD19 CAR T, shows high response rates in relapsed or refractory large B‑cell lymphoma and early remission signals in systemic lupus erythematosus.